Exendin and Exendin Agonists for Eating Disorders
AssigneeAmylin Pharmaceuticals, Inc.
InventorsANDREW A. YOUNG, SUNIL BHAVSAR, BRONISLAVA GEDULIN
Life of this patent
Estimating the term…
Abstract
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Claims20
A method for treating an eating disorder in a human in need thereof comprising administering to the human a therapeutically effective amount of an exendin-4 peptide comprising the amino acid sequence of SEQ ID NO:
- 2 to treat the eating disorder.
A method for treating an eating disorder in a human in need thereof comprising administering to the human a therapeutically effective amount of an exendin peptide or an exendin agonist analog peptide to treat the eating disorder.
A method for treating an eating disorder in a human in need thereof comprising subcutaneously administering to the human from 0.1 μg/kg/day to 10 μg/kg/day of an exendin-4 peptide comprising the amino acid sequence of SEQ ID NO:
- 2 to treat the eating disorder.
Dependencies are inferred from the claim text.